Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Simple Cervical Cancer Exams Proposed for Low-Resource Settings

By Labmedica staff writers
Posted on 12 Mar 2008
Cervical cancer, caused by the human papillomavirus (HPV), affects about 500,000 women each year and kills 270,000 worldwide annually. More...
There is a huge discrepancy between cervical cancer deaths in rich and poor nations--80-85% of deaths occur in the developing world. In developed countries, screening programs using the Pap smear are in place to spot disease and treat it early. However, a successful Pap testing program requires a high degree of organization, sophisticated laboratory equipment, and highly trained technicians. In spite of government efforts, large-scale Pap screening programs have failed in poorer regions.

During a panel presentation at the Goethe-Institut (Washington, DC, USA) on March 5, 2008, Dr. Jacqueline Sherris of PATH (formally: Program for Appropriate Technology in Health), an Alliance for Cervical Cancer Prevention (ACCP) founder, noted, "cervical cancer represents a huge global inequity with a heavy burden on poor women.”

A painless visual screening method has been found to be as effective, if not more effective, as the Pap smear. For the visual screening method, a trained health worker swabs the patient's cervix with vinegar. After one minute, any small lesions on the cervix--signs of potential future cancer--can be seen with the naked eye.

"In most cases it is possible to treat women for precancer during the same visit to the clinic,” said Dr. Harshad Sanghvi of the Johns Hopkins Program for International Education in Gynecology and Obstetrics (JHPIEGO; Baltimore, MD, USA), an ACCP partner. "This is important because if a woman is sent home the day of the exam and asked to come back days or weeks later to hear the results and be treated, she may not be able to return. In the past, many women have missed the care they needed for this reason. Treatment in the late stages of cervical cancer--when women suffer symptoms--is difficult and often not successful. We need to screen all women, beginning at age 30, and provide rapid treatment to those who need it,” Dr. Sanghvi added.

Dr. R. Sankaranarayanan, from the International Agency for Research on Cancer (IARC; Lyons, France), has studied alternatives to Pap smear screening in India and other countries. He explained that cervical cancer is easy to treat if precancerous signs are detected early. Treatment in low-resource settings often can be implemented using a device that destroys the affected tissue by freezing, the same way that common warts are frozen.

"New technologies for cervical cancer prevention are revolutionizing public health,” stated Silvana Luciani of the Pan American Health Organization (PAHO; Washington, DC, USA). "Visual screening methods, high-tech DNA tests for HPV, and the new HPV vaccines represent incredible opportunities to strengthen prevention. We need to protect girls from HPV infection with vaccine, but immunization is not a substitute for screening.

Screening programs are needed to care for women who may have already been infected with HPV, because the vaccine does not protect them effectively and there are cancer-causing types of HPV not targeted by the vaccine. Research indicates that a combination of vaccination and screening can dramatically reduce cervical cancer deaths in the coming decades.”


Related Links:
Goethe-Institut
Johns Hopkins Program for International Education in Gynecology and Obstetrics
International Agency for Research on Cancer

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: The VENTANA PTEN (SP218) RxDx Assay is a qualitative IHC assay for assessing PTEN protein in prostate adenocarcinoma, with staining performed using the OptiView DAB IHC Detection Kit on a BenchMark ULTRA instrument (Photo courtesy of Roche)

New Companion Diagnostic Expands Precision Medicine in Prostate Cancer

Prostate cancer is a leading cancer diagnosis in men and becomes particularly aggressive when it presents as metastatic, hormone-sensitive disease. Tumors with loss of phosphatase and tensin homolog (PTEN)... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.